SCHEMBL3020375

SCHEMBL3020375

COc1cc(-c2csc(N3CCN(S(=O)(=O)c4ccccc4Cl)CC3)n2)cc(OC)c1OC

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 7/20 0.57
MAPK1 P28482 5/20 0.57
GAA P10253 1/20 0.57
MAPT P10636 10/20 0.52
LMNA P02545 5/20 0.52
SMN1; SMN2 Q16637 5/20 0.52
MEN1 O00255 3/20 0.52
KMT2A Q03164 3/20 0.52
RECQL P46063 3/20 0.51
HSD17B10 Q99714 3/20 0.51
USP2 O75604 1/20 0.51
L3MBTL1 Q9Y468 2/20 0.47
KDM4E B2RXH2 1/20 0.47
NTSR1 P30989 1/20 0.47
TDP1 Q9NUW8 1/20 0.47
NPC1 O15118 1/20 0.46
RAB9A P51151 1/20 0.46
POLB P06746 1/20 0.45
FAAH O00519 1/20 0.45
EPHX2 P34913 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3009500 0.93 ALDH1A1 (0.55) ALDH1A1MAPK1GAAMAPTLMNA
SCHEMBL3018719 0.90 MAPT (0.59) ALDH1A1MAPK1GAAMAPTLMNA
SCHEMBL3009920 0.90 ALDH1A1 (0.56) ALDH1A1MAPK1GAAMAPTLMNA
SCHEMBL3012422 0.90 ALDH1A1 (0.56) ALDH1A1MAPK1GAAMAPTLMNA
SCHEMBL3016927 0.90 ALDH1A1 (0.56) ALDH1A1MAPK1GAAMAPTLMNA
SCHEMBL3013930 0.88 MAPT (0.59) ALDH1A1MAPK1GAAMAPTLMNA
SCHEMBL3022136 0.88 MAPK1 (0.54) ALDH1A1MAPK1GAAMAPTLMNA
SCHEMBL3013056 0.88 MAPT (0.55) ALDH1A1MAPK1GAAMAPTLMNA
SCHEMBL3016151 0.88 ALDH1A1 (0.56) ALDH1A1MAPK1GAAMAPTLMNA
SCHEMBL3018535 0.87 PKM (0.56) ALDH1A1MAPK1GAAMAPTLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2188272-B1 PHENYL- AND BENZYLTHIAZOLYLPIPERAZINE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES REMYND NV (BE) 2016-02-24 EP disclosed
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA ALDH1A1 3510/4885MAPK1 2767/4885GAA 110/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.